title: Bosutinib: a SRC-ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia.
abstract: Bosutinib is one of five tyrosine kinase inhibitors commercially available in the United States for the treatment of chronic myeloid leukemia. This review of bosutinib summarizes the mode of action, pharmacokinetics, efficacy and safety data, as well as the patient-focused perspective through quality-of-life data. Bosutinib has shown considerable and sustained efficacy in chronic myeloid leukemia, especially in the chronic phase, with resistance or intolerance to prior tyrosine kinase inhibitors. Bosutinib has distinct but manageable adverse events. In the absence of T315I and V299L mutations, there are no absolute contraindications for the use of bosutinib in this patient population.
authors.affiliation: Division of Hematology, Department of Hematology and Medical Oncology, the Winship Cancer Institute at Emory University, Atlanta, Georgia, USA.
authors.forename: Fuad El
authors.initials: FE
authors.lastname: Rassi
authors.forename: Hanna Jean
authors.initials: HJ
authors.lastname: Khoury
keywords: SRC-ABL kinase inhibitor; bosutinib; chronic myeloid leukemia; clinical activity; review; treatment
references.citation: Leukemia. 2009 Mar;23(3):477-85
references.pmid: 19039322
references.citation: Ann Intern Med. 2006 Dec 19;145(12):913-23
references.pmid: 17179059
references.citation: J Clin Oncol. 2011 Jun 20;29(18):2514-20
references.pmid: 21576640
references.citation: Blood. 2012 Apr 12;119(15):3403-12
references.pmid: 22371878
references.citation: N Engl J Med. 1999 Jul 15;341(3):164-72
references.pmid: 10403855
references.citation: Cancer. 2012 Jun 15;118(12):3123-7
references.pmid: 22294282
references.citation: J Clin Oncol. 2012 Oct 1;30(28):3486-92
references.pmid: 22949154
references.citation: Am J Hematol. 2012 Nov;87(11):E125-8
references.pmid: 23044928
references.citation: Cancer Res. 2006 Dec 1;66(23):11314-22
references.pmid: 17114238
references.citation: Blood. 2001 Nov 15;98(10):3074-81
references.pmid: 11698293
references.citation: Cancer Chemother Pharmacol. 2012 Jan;69(1):221-7
references.pmid: 21691746
references.citation: N Engl J Med. 1999 Apr 29;340(17):1330-40
references.pmid: 10219069
references.citation: N Engl J Med. 2003 Mar 13;348(11):994-1004
references.pmid: 12637609
references.citation: Leukemia. 2000 Mar;14(3):389-92
references.pmid: 10720131
references.citation: Leuk Res. 2012 Apr;36(4):438-42
references.pmid: 22036634
references.citation: Blood. 2011 Oct 27;118(17):4567-76
references.pmid: 21865346
references.citation: Blood. 2010 Nov 11;116(19):3758-65
references.pmid: 20679528
references.citation: CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30
references.pmid: 16514137